DIPHERELINE P.R. POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial
Product details
Registration number: SIN14634P
Classification: Prescription Only
Active ingredients: TRIPTORELIN ACETATE 4.9 mg eqv TRIPTORELIN
Strength: 3.75 mg/vial
Dosage form: INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE
Route: INTRAMUSCULAR
Registrant: IPSEN PHARMA SINGAPORE PTE. LTD.
ATC code: L02AE04
HSA approval date: 25 September 2014
Manufacturer(s):
- IPSEN PHARMA BIOTECH (Lyophilisate manufacturer)
- CENEXI (Solvent manufacturer)
- Ipsen Pharma Biotech (Gamma irradiation site of lyophilisate)
- Sterigenics Italy S.P.A (Gamma irradiation site of lyophilisate)
- Sterigenics Belgium (Gamma irradiation site of lyophilisate)
Manufacturing country/countries: FRANCE; ITALY; BELGIUM
What are the HSA registration number and classification for DIPHERELINE P.R. POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial?
According to the HSA dataset updated 7 August 2026:
Registration number: SIN14634P
Classification: Prescription Only
What active ingredients and strength are recorded for DIPHERELINE P.R. POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial?
According to the HSA dataset updated 7 August 2026:
Active ingredients: TRIPTORELIN ACETATE 4.9 mg eqv TRIPTORELIN
Strength: 3.75 mg/vial
Ingredients and strengths are listed separately as recorded by HSA; their positions do not establish a one-to-one match. This is not a dosing instruction.
What dosage form and route are recorded for DIPHERELINE P.R. POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial?
According to the HSA dataset updated 7 August 2026:
Dosage form: INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE
Route: INTRAMUSCULAR
Who is the recorded registrant for DIPHERELINE P.R. POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial?
According to the HSA dataset updated 7 August 2026:
Registrant: IPSEN PHARMA SINGAPORE PTE. LTD.
Which manufacturers and countries are listed for DIPHERELINE P.R. POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial?
According to the HSA dataset updated 7 August 2026:
Manufacturer(s):
- IPSEN PHARMA BIOTECH (Lyophilisate manufacturer)
- CENEXI (Solvent manufacturer)
- Ipsen Pharma Biotech (Gamma irradiation site of lyophilisate)
- Sterigenics Italy S.P.A (Gamma irradiation site of lyophilisate)
- Sterigenics Belgium (Gamma irradiation site of lyophilisate)
Manufacturing country/countries: FRANCE; ITALY; BELGIUM
Where can I look up DIPHERELINE P.R. POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial in the HSA register?
Open HSA’s therapeutic product register and search for registration number SIN14634P or the exact product name DIPHERELINE P.R. POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial. The general register link does not preselect this product.
What are the source dates for this DIPHERELINE P.R. POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial record?
This record is from HSA’s List of Registered Therapeutic Products on data.gov.sg. Dataset update: 7 August 2026. Retrieval date: 13 November 2026.
The dataset date is a snapshot date, not a separate current-register check for every product. Later direct checks are recorded separately.
Has this DIPHERELINE P.R. POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial record had a separate HSA register check?
No separate current-register check is recorded for this product. Its presence in the imported dataset does not establish its current registration status.
Search the HSA register using SIN14634P for the latest record.
Sources and dates
HSA dataset: 2026. Updated: 13 November 2026.
Factual product information only; no dosing, treatment or suitability advice.
Updated and reviewed by: Dr Joel Lim MBChB UK (PG Dip Dermatology), Resident Physician.
.png)